发明名称 Electrocardiographic aspects of CHF treatment
摘要 In accordance with the present invention, it has been found that prolonged QT-c intervals in mammalian patients, indicative of susceptibility of the patients to arrhythmia and sudden cardiac death, can be reduced by a process in which an aliquot of the patient's blood is removed and stressed extracorporeally, by application thereto of oxidative stress and electromagnetic radiation such as ultraviolet light, and then re-injected into the patient. Such treatment results in a significant reduction in QT-c interval in the patients, indicative of reduced susceptibility to arrhythmia and sudden cardiac death. In clinical trials described in the Examples section below, this reduction in QT-c interval was associated with a marked reduction in sudden cardiac death. There are also indications that, in the absence of treatment according to the invention, the patients would have exhibited a lengthening of their QT-c intervals.
申请公布号 AU2003218583(A2) 申请公布日期 2003.10.27
申请号 AU20030218583 申请日期 2003.04.10
申请人 VASOGEN IRELAND LIMITED 发明人 ELDON, R. SMITH;GUILLERMO TORRE-AMIONE
分类号 A61K35/14;A61K41/00;A61M1/36;A61N5/00;A61P9/04;A61P9/06 主分类号 A61K35/14
代理机构 代理人
主权项
地址
您可能感兴趣的专利